At Connect Biopharma, I provide risk-based oversight of clinical sites, prioritizing participant safety, critical data, and protocol adherence. I oversee CRA/CRO monitoring and review documentation and site performance to identify quality or compliance gaps.
I coordinate clinical vendors and follow corrective actions through resolution. I also lead site qualification, initiation, interim monitoring, and close-out activities, working with study leadership on enrollment, data quality, and milestones.
At NCGS, Inc. (now Novotech), I managed up to 14 investigational sites across multiple protocols, monitoring enrollment, compliance, and data quality. I trained and provided oversight to CRA I/II personnel on SOPs, monitoring expectations, and site assessment practices.
Across my clinical research work, I’ve supported studies from start-up through close-out and worked with sponsors and study teams on protocol deviations, site risks, and inspection readiness. My therapeutic experience includes cardiovascular, CNS/neurology, dermatology, and oncology studies.
